A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry

Fauvelle, Catherine; Lambotin, Mélanie; Heydmann, Laura; Prakash, Ekambaranellore; Bhaskaran, Sunil; Baumert, Thomas F.; Moog, Christiane

doi:10.1007/s12072-017-9809-y

Cited by 17 publications

(13 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extensive research has been conducted for antiviral screening of novel compounds using HCVpp system [ 43 , 44 , 45 , 46 , 47 , 48 ]. This system allows for studying the role of glycoproteins in HCV entry, to identify receptors important during attachment process or to gain the important knowledge about the internalization process [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars

et al. 2018

View full text Add to dashboard Cite

Hepatitis C virus (HCV), the etiological agent of the most common and dangerous diseases of the liver, is a major health problem worldwide. Despite many attempts, there is still no vaccine available. Although many drugs have been approved for use mostly in combination regimen, their high costs make them out of reach in less developed regions. Previously, we have synthesized a series of compounds belonging to uridine derivatives of 2-deoxy sugars and have proved that some of them possess antiviral activity against influenza A virus associated with N-glycosylation inhibition. Here, we analyze the antiviral properties of these compounds against HCV. Using cell culture-derived HCV (HCVcc), HCV pseudoparticles (HCVpp), and replicon cell lines, we have shown high anti-HCV activity of two compounds. Our results indicated that compounds 2 and 4 significantly reduced HCVcc propagation with IC50 values in low μM range. Further experiments using the HCVpp system confirmed that both compounds significantly impaired the infectivity of produced HCVpp due to the inhibition of the correct maturation of viral glycoproteins. Overall, our results suggest that inhibiting the glycosylation process might be a good target for new therapeutics not only against HCV, but other important viral pathogens which contain envelopes with highly glycosylated proteins.

show abstract

Section: Discussionmentioning

confidence: 99%

Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Moreover, some compounds, such as lycorine, emodin, and procyanidin, have been proven to be effective in inhibiting flavivirus or HCV infections via different mechanisms (16)(17)(18)(19)(20). Our high-content screening assay design could identify compounds that inhibit JEV viral entry, translation, and RNA synthesis.…”

Section: Ouabain Blocks Jev Infectionmentioning

confidence: 99%

Screening of Natural Extracts for Inhibitors against Japanese Encephalitis Virus Infection

Guo

Jia

Liu

et al. 2020

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The mosquito-borne Japanese encephalitis virus (JEV) causes serious illness worldwide that is associated with high morbidity and mortality. Currently, there are no effective drugs approved for the treatment of JEV infection. Drug-repurposing screening is an alternative approach to discover potential antiviral agents. In this study, high-content screening (HCS) of a natural extracts library was performed, and two hit FDA-approved Na ϩ /K ϩ -ATPase inhibitors, ouabain and digoxin, were identified as having robust efficiency against JEV infection with the selectivity indexes over 1,000. The results indicated that ouabain and digoxin blocked the JEV infection at the replication stage by targeting the Na ϩ /K ϩ -ATPase. Furthermore, it was proven that ouabain significantly reduced the morbidity and mortality caused by JEV in a BALB/c mouse model. This work demonstrated that Na ϩ /K ϩ -ATPase could serve as the target of treatment of JEV infection, and ouabain has the potential to be developed as an effective anti-JEV drug.Ethics statements and mice. All animal experimental procedures were carried out according to ethical guidelines and were approved by the Animal Care Committee of the Wuhan Institute of Virology (permit number, WIVA25201705).Cells and viruses. BHK-21, Vero, and Huh-7 cells were maintained in Dulbecco modified Eagle medium (DMEM) (HyClone, Logan, UT, USA) supplement with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA). U251 cells were maintained in minimum essential medium (MEM) (HyClone) supplement with 10% FBS. JEV AT31 and SA14 strains were generated by using the infectious clones of pMWJEAT-AT31 (kindly provided by T. Wakita, Tokyo Metropolitan Institute for Neuroscience) and pACYC-JEV-SA14 (GenBank accession no. U14163) as previously described (32), respectively. The infectious clone plasmids were linearized, subjected to in vitro transcription, and electroporated into BHK-21 cells. Three days later, the supernatant was collected and stored at Ϫ80°C in aliquots (33, 34). The virus stocks were propagated and titrated by a plaque assay in BHK-21 cells.Optimization of HCS assay conditions. The cell density, infective dose, and assay endpoint were optimized for the HCS assay. Different densities (2,000 to 10,000 cells per well) of Vero cells were infected at MOI values ranging from 0.2 to 1. Cell viability was detected at different times (24 to 72 h) after JEV inoculation. The appropriate cell density, infective dose, and assay endpoint for the HCS assay were selected by comparing the signal-to-basal ratio (S/B), the coefficient of variation (CV), and z values under different conditions as previously described (11); 10 M manidipine and 0.5% DMSO were used as positive and negative controls, respectively.HCS assay of drug library screening. A library of 1,034 compounds from natural extracts was purchased from Weikeqi Biotech (Sichuan, China). Compounds were stored as 10 mM stock solutions in DMSO at -80°C until use. As shown in Fig. 1A, Vero cells were dissociated and seeded at a density of ...

show abstract

“…In vitro study by Brochot et al have depicted that cinnamon along with some other medicines could be highly effective in acute and chronic human infections either bacterial, viral or fungal [100]. Procyanidin type A, a cinnamon derived compound, inhibits hepatitis C virus cell entry as studied by Catherine Fauvelle and associates [101]. This proves the potential of cinnamon against the dreadful viruses.…”

Section: Cinnamon (Darchini) (Cinnamomum Zeylanicum)mentioning

confidence: 96%

Immunomodulators for Curtailing COVID-19: a Positive Approach

Bhat

Rather

Iqbal

et al. 2020

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is highly infectious, spreading swiftly from man to man which has not been previously recognized in humans. World Health Organization (WHO) on February 11, 2020 named the infection as COVID-19 as an acronym for ‘coronavirus disease-2019’ and on March 11, 2020 declared the outbreak as pandemic. It affects all the people without discrimination, however, older, immune compromised are more susceptible. The virus chiefly spread through droplet infection from infected person to healthy one by coughing, sneezing or with infected hands when touched to eyes, nose or mouth. Symptoms of the infection range from mild to severe ones. In severe cases (approx. 14% of cases) fever typically of high grade (104oF), breathlessness, pneumonia and severe acute respiratory syndrome may appear. So far no specific treatment or vaccine for novel coronavirus-2019 is there. From the past and recent past experiences we have learnt that herbal medicines have proven beneficial against various dreadful viral infections. Assessment of immune enhancing herbs in this paper may definitely be helpful for the body to fight COVID-19 infection. Keywords: Severe acute respiratory syndrome coronavirus-2, COVID-19, Pneumonia, Immune, Herbs

show abstract

A cinnamon-derived procyanidin type A compound inhibits hepatitis C virus cell entry

Abstract: The natural compound IND02 exhibits potent HCV cell entry inhibition and provides a novel perspective for development of a low-cost antiviral for treatment of HCV infection.

Cited by 17 publications

References 25 publications

Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars

Anti-Hepatitis C Virus Activity of Uridine Derivatives of 2-Deoxy Sugars

Screening of Natural Extracts for Inhibitors against Japanese Encephalitis Virus Infection

Immunomodulators for Curtailing COVID-19: a Positive Approach

Contact Info

Product

Resources

About